Shreya Jitendra Shah, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shah’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A137720 · Current
Licensed to practise in California · since 2015 · expires 2028-10-31 · Northwestern University Feinberg School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$8,867
Medicare paid this office $8,867 for 98 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 54 | $3,103 | $51 |
| Return visit (30+ min) | 31 | $2,164 | $52 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 32 | $2,094 | $65 |
| Long return visit (40+ min) | 14 | $809 | $51 |
Who their Medicare patients are
98 Original Medicare patients in 2024. Average age 73 · Women 52% · Also on Medicaid 14% · Health risk score 1.04. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 44% · Coronary heart disease 20% · Depression 19% · Atrial fibrillation 15% · Diabetes 14% · Cancer 14% · Chronic kidney disease 13%.
The office billed $71,095, Medicare allowed $13,410 and paid $8,867; for 166 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 98 | 166 | 73 | 1.04 | $71,095 | $8,867 |
| 2023 | 99 | 185 | 72 | 1.10 | $82,703 | $10,754 |
| 2022 | 57 | 141 | 72 | 1.13 | $70,856 | $7,173 |
| 2021 | 90 | 252 | 72 | 1.10 | $95,259 | $15,854 |
| 2020 | 113 | 273 | 72 | 1.12 | $77,872 | $15,775 |
| 2019 | 116 | 232 | 71 | 1.24 | $31,065 | $13,787 |
| 2018 | 136 | 265 | 72 | 1.14 | $25,442 | $15,771 |
| 2017 | 44 | 54 | 70 | 0.95 | $6,199 | $3,313 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 37 | $3,222 | $62 |
| Short return visit (20+ min) | 50 | $2,939 | $51 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 43 | $2,783 | $65 |
| Telehealth originating site facility fee | 12 | $292 | $21 |
2022: 5 services
| Return visit (30+ min) | 24 | $2,038 | $68 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $1,681 | $70 |
| Short return visit (20+ min) | 20 | $1,135 | $49 |
| Telehealth originating site facility fee | 26 | $739 | $19 |
| Long return visit (40+ min) | 12 | $723 | $52 |
2021: 8 services
| Return visit (30+ min) | 47 | $4,327 | $65 |
| Long return visit (40+ min) | 23 | $2,555 | $102 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $2,385 | $82 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 16 | $1,677 | $105 |
| Short return visit (20+ min) | 28 | $1,671 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $837 | $56 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $452 | $28 |
| Telehealth originating site facility fee | 22 | $449 | $20 |
2020: 5 services
| Return visit (30+ min) | 62 | $6,552 | $64 |
| Short return visit (20+ min) | 56 | $3,672 | $47 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $1,663 | $49 |
| New patient visit (45+ min) | 15 | $1,661 | $111 |
| Telephone medical discussion with physician, 5-10 minutes | 15 | $383 | $24 |
2019: 3 services
| Return visit (30+ min) | 72 | $8,427 | $60 |
| Short return visit (20+ min) | 56 | $2,403 | $41 |
| New patient visit (45+ min) | 13 | $1,126 | $87 |
2018: 3 services
| Return visit (30+ min) | 67 | $8,872 | $65 |
| Short return visit (20+ min) | 70 | $3,104 | $37 |
| New patient visit (45+ min) | 26 | $2,306 | $89 |
2017: 1 service
| Short return visit (20+ min) | 26 | $1,135 | $44 |
Drugs they prescribed that Part D paid
$88,770
Pharmacies billed $88,770 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
662 generic and 91 brand-name prescriptions · $88,770 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 18 | $31,086 | $1,727 |
| Jardiance | 29 | $30,741 | $1,060 |
| Gabapentin | 27 | $1,108 | $41 |
| Duloxetine | 19 | $665 | $35 |
| Atorvastatin | 74 | $622 | $8 |
See all 17 drugs
| Eliquis | 18 | $31,086 | $1,727 |
| Jardiance | 29 | $30,741 | $1,060 |
| Gabapentin | 27 | $1,108 | $41 |
| Duloxetine | 19 | $665 | $35 |
| Atorvastatin | 74 | $622 | $8 |
| Rosuvastatin | 32 | $601 | $19 |
| Losartan | 42 | $480 | $11 |
| Levothyroxine | 47 | $467 | $10 |
| Omeprazole | 20 | $286 | $14 |
| Simvastatin | 15 | $278 | $19 |
| Amlodipine Besylate | 50 | $258 | $5 |
| Lisinopril | 24 | $241 | $10 |
| Metoprolol | 13 | $239 | $18 |
| Sertraline | 17 | $200 | $12 |
| Citalopram Hbr | 12 | $132 | $11 |
| Hydrochlorothiazide | 21 | $128 | $6 |
| Metformin | 12 | $41 | $3 |
Year by year
| 2024 | 766 | 113 | None | 12% | $88,770 |
| 2023 | 691 | 126 | None | 14% | $102,850 |
| 2022 | 598 | 78 | 0% (0) | None | $89,477 |
| 2021 | 917 | 97 | 1% (12) | None | $96,422 |
| 2020 | 787 | 104 | None | None | $79,413 |
| 2019 | 669 | 114 | None | None | $68,169 |
| 2018 | 551 | 112 | None | None | $59,425 |
| 2017 | 87 | 32 | None | 28% | $8,886 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Eliquis | 19 | $33,897 | $1,784 |
| Jardiance | 13 | $19,511 | $1,501 |
| Duloxetine | 15 | $1,249 | $83 |
| Gabapentin | 21 | $1,227 | $58 |
| Atorvastatin | 62 | $1,037 | $17 |
| Losartan | 57 | $1,009 | $18 |
| Omeprazole | 17 | $685 | $40 |
| Rosuvastatin | 26 | $657 | $25 |
| Lisinopril | 36 | $540 | $15 |
| Metformin | 14 | $490 | $35 |
| Amlodipine Besylate | 30 | $456 | $15 |
| Levothyroxine | 31 | $453 | $15 |
| Simvastatin | 11 | $216 | $20 |
| Hydrochlorothiazide | 12 | $48 | $4 |
2022: 16 drugs
| Eliquis | 14 | $22,639 | $1,617 |
| Trulicity | 11 | $14,213 | $1,292 |
| Sumatriptan | 13 | $8,767 | $674 |
| Synthroid | 14 | $1,417 | $101 |
| Gabapentin | 16 | $981 | $61 |
| Atorvastatin | 73 | $796 | $11 |
| Levothyroxine | 30 | $449 | $15 |
| Rosuvastatin | 26 | $423 | $16 |
| Metformin | 13 | $385 | $30 |
| Omeprazole | 12 | $355 | $30 |
| Lisinopril | 39 | $355 | $9 |
| Losartan | 31 | $281 | $9 |
| Trazodone | 15 | $220 | $15 |
| Simvastatin | 14 | $168 | $12 |
| Amlodipine Besylate | 21 | $139 | $7 |
| Hydrochlorothiazide | 15 | $39 | $3 |
2021: 24 drugs
| Eliquis | 13 | $16,158 | $1,243 |
| Trulicity | 14 | $15,344 | $1,096 |
| Sumatriptan | 14 | $8,869 | $634 |
| Estradiol | 14 | $1,516 | $108 |
| Atorvastatin | 97 | $1,423 | $15 |
| Gabapentin | 36 | $1,323 | $37 |
| Levothyroxine | 54 | $1,266 | $23 |
| Losartan | 29 | $881 | $30 |
| Duloxetine | 18 | $791 | $44 |
| Omeprazole | 30 | $674 | $22 |
| Ezetimibe | 13 | $645 | $50 |
| Amlodipine Besylate | 42 | $466 | $11 |
| Lisinopril | 44 | $418 | $10 |
| Diclofenac | 12 | $374 | $31 |
| Trazodone | 27 | $354 | $13 |
| Metformin | 20 | $281 | $14 |
| Simvastatin | 16 | $275 | $17 |
| Rosuvastatin | 27 | $254 | $9 |
| Tamsulosin | 11 | $210 | $19 |
| Metformin Hcl Er | 17 | $154 | $9 |
| Fluoxetine | 11 | $146 | $13 |
| Finasteride | 11 | $145 | $13 |
| Hydrocodone-Acetaminophen | 11 | $125 | $11 |
| Zolpidem | 16 | $120 | $7 |
2020: 18 drugs
| Eliquis | 14 | $17,399 | $1,243 |
| Sumatriptan | 12 | $10,166 | $847 |
| Gabapentin | 32 | $1,216 | $38 |
| Atorvastatin | 78 | $1,116 | $14 |
| Levothyroxine | 30 | $812 | $27 |
| Rosuvastatin | 12 | $797 | $66 |
| Omeprazole | 35 | $735 | $21 |
| Duloxetine | 17 | $658 | $39 |
| Lisinopril | 29 | $327 | $11 |
| Amlodipine Besylate | 35 | $312 | $9 |
| Losartan | 19 | $268 | $14 |
| Metformin | 20 | $265 | $13 |
| Alendronate | 15 | $262 | $17 |
| Trazodone | 20 | $259 | $13 |
| Fluticasone Propionate | 11 | $209 | $19 |
| Hydrochlorothiazide | 29 | $191 | $7 |
| Furosemide | 15 | $88 | $6 |
| Zolpidem | 15 | $84 | $6 |
2019: 14 drugs
| Atorvastatin | 60 | $1,124 | $19 |
| Gabapentin | 32 | $1,005 | $31 |
| Duloxetine | 15 | $832 | $55 |
| Levothyroxine | 19 | $556 | $29 |
| Diltiazem 24hr Er (Cd) | 11 | $428 | $39 |
| Omeprazole | 19 | $359 | $19 |
| Losartan | 27 | $316 | $12 |
| Metformin Hcl Er | 13 | $248 | $19 |
| Metformin | 18 | $230 | $13 |
| Metoprolol | 13 | $225 | $17 |
| Lisinopril | 20 | $159 | $8 |
| Hydrochlorothiazide | 24 | $149 | $6 |
| Amlodipine Besylate | 19 | $142 | $7 |
| Furosemide | 20 | $89 | $4 |
2018: 13 drugs
| Atorvastatin | 54 | $1,169 | $22 |
| Diltiazem 24hr Er (Cd) | 11 | $763 | $69 |
| Losartan | 31 | $479 | $15 |
| Metoprolol | 13 | $453 | $35 |
| Levothyroxine | 12 | $329 | $27 |
| Gabapentin | 12 | $276 | $23 |
| Amlodipine Besylate | 22 | $229 | $10 |
| Pantoprazole | 11 | $166 | $15 |
| Lisinopril | 16 | $147 | $9 |
| Hydrochlorothiazide | 15 | $112 | $7 |
| Metformin Hcl Er | 11 | $110 | $10 |
| Metformin | 14 | $101 | $7 |
| Furosemide | 17 | $78 | $5 |
Money from drug and device companies
$38 in 2025
A payment is not proof that care is biased.
| Biogen | Leqembi | $38 | 2 payments
|
See all 2 published payments
| Biogen | Meals · 2025-11-03 | Leqembi | $21 |
| Biogen | Meals · 2025-05-20 | Leqembi | $17 |
Professional record
- NPI
- 1255750956
- Licence
- CA A137720California A137720: Current · expires 2028-10-31
- Trained
- Northwestern University Feinberg Medical School, 2014
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Federal specialty code 2083C0008X (2083C0008X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-04-09
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.